Published in Blood on April 24, 2003
In situ vaccination against mycosis fungoides by intratumoral injection of a TLR9 agonist combined with radiation: a phase 1/2 study. Blood (2011) 2.02
Immunopathogenesis and therapy of cutaneous T cell lymphoma. J Clin Invest (2005) 2.01
Trial watch: Dendritic cell-based interventions for cancer therapy. Oncoimmunology (2012) 1.51
Targeting the local tumor microenvironment with vaccinia virus expressing B7.1 for the treatment of melanoma. J Clin Invest (2005) 1.24
Synthetic Nanoparticles for Vaccines and Immunotherapy. Chem Rev (2015) 1.10
A gynecologic oncology group phase II trial of two p53 peptide vaccine approaches: subcutaneous injection and intravenous pulsed dendritic cells in high recurrence risk ovarian cancer patients. Cancer Immunol Immunother (2011) 1.04
Developing idiotype vaccines for lymphoma: from preclinical studies to phase III clinical trials. Br J Haematol (2008) 1.04
A Phase I vaccine trial using dendritic cells pulsed with autologous oxidized lysate for recurrent ovarian cancer. J Transl Med (2013) 0.99
Expression of T-plastin, FoxP3 and other tumor-associated markers by leukemic T-cells of cutaneous T-cell lymphoma. Leuk Lymphoma (2008) 0.97
IRAK-M removal counteracts dendritic cell vaccine deficits in migration and longevity. J Immunol (2010) 0.97
Day-4 myeloid dendritic cells pulsed with whole tumor lysate are highly immunogenic and elicit potent anti-tumor responses. PLoS One (2011) 0.97
Optimizing dendritic cell vaccine for immunotherapy in multiple myeloma: tumour lysates are more potent tumour antigens than idiotype protein to promote anti-tumour immunity. Clin Exp Immunol (2012) 0.90
Haematological malignancies: at the forefront of immunotherapeutic innovation. Nat Rev Cancer (2015) 0.88
Optimizing parameters for clinical-scale production of high IL-12 secreting dendritic cells pulsed with oxidized whole tumor cell lysate. J Transl Med (2011) 0.88
Ex vivo induction of viral antigen-specific CD8 T cell responses using mRNA-electroporated CD40-activated B cells. Clin Exp Immunol (2005) 0.87
Heat-shocked tumor cell lysate-pulsed dendritic cells induce effective anti-tumor immune response in vivo. World J Gastroenterol (2006) 0.86
Enhancement of dendritic cells as vaccines for cancer. Immunotherapy (2010) 0.86
Immune cell recruitment and cell-based system for cancer therapy. Pharm Res (2007) 0.83
Interferon-alpha and viral triggers promote functional maturation of human monocyte-derived dendritic cells. Br J Dermatol (2008) 0.80
Uric acid enhances the antitumor immunity of dendritic cell-based vaccine. Sci Rep (2015) 0.76
Intralymphatic Administration of Adipose Mesenchymal Stem Cells Reduces the Severity of Collagen-Induced Experimental Arthritis. Front Immunol (2017) 0.76
Biodistribution and Efficacy of Human Adipose-Derived Mesenchymal Stem Cells Following Intranodal Administration in Experimental Colitis. Front Immunol (2017) 0.75
Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med (2011) 45.46
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. N Engl J Med (2015) 14.71
COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature (2010) 14.62
High-throughput oncogene mutation profiling in human cancer. Nat Genet (2007) 12.68
WHO-EORTC classification for cutaneous lymphomas. Blood (2005) 12.14
Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med (2012) 11.72
Plasmacytoid dendritic cells sense self-DNA coupled with antimicrobial peptide. Nature (2007) 8.88
A genome-wide association study identifies new psoriasis susceptibility loci and an interaction between HLA-C and ERAP1. Nat Genet (2010) 8.48
Integrative analysis of the melanoma transcriptome. Genome Res (2010) 8.46
Mapping cis- and trans-regulatory effects across multiple tissues in twins. Nat Genet (2012) 6.97
MEK1 mutations confer resistance to MEK and B-RAF inhibition. Proc Natl Acad Sci U S A (2009) 6.58
Modeling genomic diversity and tumor dependency in malignant melanoma. Cancer Res (2008) 5.95
The architecture of gene regulatory variation across multiple human tissues: the MuTHER study. PLoS Genet (2011) 5.95
Improved overall survival in melanoma with combined dabrafenib and trametinib. N Engl J Med (2014) 5.65
Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance. Nature (2013) 4.90
MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study. Lancet Oncol (2013) 4.26
The Genetic Evolution of Melanoma from Precursor Lesions. N Engl J Med (2015) 4.24
Identification of 15 new psoriasis susceptibility loci highlights the role of innate immunity. Nat Genet (2012) 4.13
Plasmacytoid predendritic cells initiate psoriasis through interferon-alpha production. J Exp Med (2005) 4.04
The IL-23/Th17 axis in the immunopathogenesis of psoriasis. J Invest Dermatol (2009) 3.93
In vivo switching of human melanoma cells between proliferative and invasive states. Cancer Res (2008) 3.66
Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial. Lancet (2008) 3.62
Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial. Lancet (2005) 3.59
Metastatic potential of melanomas defined by specific gene expression profiles with no BRAF signature. Pigment Cell Res (2006) 3.42
Negative regulation of interferon-regulatory factor 3-dependent innate antiviral response by the prolyl isomerase Pin1. Nat Immunol (2006) 2.85
Sequence variants in the genes for the interleukin-23 receptor (IL23R) and its ligand (IL12B) confer protection against psoriasis. Hum Genet (2007) 2.78
Multifocal epithelial tumors and field cancerization from loss of mesenchymal CSL signaling. Cell (2012) 2.75
Alpha1beta1 integrin is crucial for accumulation of epidermal T cells and the development of psoriasis. Nat Med (2007) 2.70
Spontaneous development of psoriasis in a new animal model shows an essential role for resident T cells and tumor necrosis factor-alpha. J Exp Med (2004) 2.63
Phase II, open-label, randomized trial of the MEK1/2 inhibitor selumetinib as monotherapy versus temozolomide in patients with advanced melanoma. Clin Cancer Res (2011) 2.52
Psoriasis and systemic inflammatory diseases: potential mechanistic links between skin disease and co-morbid conditions. J Invest Dermatol (2010) 2.46
Identification of ZNF313/RNF114 as a novel psoriasis susceptibility gene. Hum Mol Genet (2008) 2.42
Long-term results of the randomized phase III trial EORTC 18991 of adjuvant therapy with pegylated interferon alfa-2b versus observation in resected stage III melanoma. J Clin Oncol (2012) 2.42
Recent insights into the immunopathogenesis of psoriasis provide new therapeutic opportunities. J Clin Invest (2004) 2.34
Mutations in IL36RN/IL1F5 are associated with the severe episodic inflammatory skin disease known as generalized pustular psoriasis. Am J Hum Genet (2011) 2.21
Psoriasis. Annu Rev Pathol (2011) 2.21
Novel MITF targets identified using a two-step DNA microarray strategy. Pigment Cell Melanoma Res (2008) 2.14
Selumetinib plus dacarbazine versus placebo plus dacarbazine as first-line treatment for BRAF-mutant metastatic melanoma: a phase 2 double-blind randomised study. Lancet Oncol (2013) 2.13
Human CD271-positive melanoma stem cells associated with metastasis establish tumor heterogeneity and long-term growth. Cancer Res (2011) 2.08
Expression of CXC chemokine receptor-4 enhances the pulmonary metastatic potential of murine B16 melanoma cells. Cancer Res (2002) 2.06
The price of tumor control: an analysis of rare side effects of anti-CTLA-4 therapy in metastatic melanoma from the ipilimumab network. PLoS One (2013) 2.01
Psoriasis triggered by toll-like receptor 7 agonist imiquimod in the presence of dermal plasmacytoid dendritic cell precursors. Arch Dermatol (2004) 1.96
Hypoxia contributes to melanoma heterogeneity by triggering HIF1α-dependent phenotype switching. J Invest Dermatol (2013) 1.91
EGFR signalling as a negative regulator of Notch1 gene transcription and function in proliferating keratinocytes and cancer. Nat Cell Biol (2008) 1.88
Resident CD141 (BDCA3)+ dendritic cells in human skin produce IL-10 and induce regulatory T cells that suppress skin inflammation. J Exp Med (2012) 1.81
Mechanisms underlying imiquimod-induced regression of basal cell carcinoma in vivo. Arch Dermatol (2003) 1.81
Identification of a novel proinflammatory human skin-homing Vγ9Vδ2 T cell subset with a potential role in psoriasis. J Immunol (2011) 1.79
Granulomatous mycosis fungoides and granulomatous slack skin: a multicenter study of the Cutaneous Lymphoma Histopathology Task Force Group of the European Organization For Research and Treatment of Cancer (EORTC). Arch Dermatol (2008) 1.78
Extended schedule, escalated dose temozolomide versus dacarbazine in stage IV melanoma: final results of a randomised phase III study (EORTC 18032). Eur J Cancer (2011) 1.78
Induction of genes mediating interferon-dependent extracellular trap formation during neutrophil differentiation. J Biol Chem (2004) 1.78
The IL23R R381Q gene variant protects against immune-mediated diseases by impairing IL-23-induced Th17 effector response in humans. PLoS One (2011) 1.71
A model for harmonizing flow cytometry in clinical trials. Nat Immunol (2010) 1.70
Dyscrasias with "undetermined significance". Arch Dermatol (2005) 1.70
Oligonucleotide array-CGH identifies genomic subgroups and prognostic markers for tumor stage mycosis fungoides. J Invest Dermatol (2009) 1.65
Consistent expression of the stem cell renewal factor BMI-1 in primary and metastatic melanoma. Int J Cancer (2007) 1.62
Cutting edge: A critical functional role for IL-23 in psoriasis. J Immunol (2010) 1.61
Angiolymphoid hyperplasia with eosinophilia: evidence for a T-cell lymphoproliferative origin. Hum Pathol (2002) 1.58
Skin problems associated with pegylated liposomal doxorubicin-more than palmoplantar erythrodysesthesia syndrome. Eur J Dermatol (2008) 1.58
Human regulatory T cells with alloantigen specificity are more potent inhibitors of alloimmune skin graft damage than polyclonal regulatory T cells. Sci Transl Med (2011) 1.56
Martorell hypertensive ischemic leg ulcer: a model of ischemic subcutaneous arteriolosclerosis. Arch Dermatol (2010) 1.55
Update on erythrodermic cutaneous T-cell lymphoma: report of the International Society for Cutaneous Lymphomas. J Am Acad Dermatol (2002) 1.54
Recombinant measles virus induces cytolysis of cutaneous T-cell lymphoma in vitro and in vivo. J Invest Dermatol (2006) 1.52
WHO/EORTC classification of cutaneous lymphomas 2005: histological and molecular aspects. J Cutan Pathol (2005) 1.51
Sox10 promotes the formation and maintenance of giant congenital naevi and melanoma. Nat Cell Biol (2012) 1.48
Special considerations for stage IV melanoma during pregnancy. Arch Dermatol (2005) 1.46
Disease-independent skin recruitment and activation of plasmacytoid predendritic cells following imiquimod treatment. J Natl Cancer Inst (2005) 1.46
Immunopathogenesis of psoriasis. Clin Rev Allergy Immunol (2007) 1.46
Atypical melanocytic proliferations and new primary melanomas in patients with advanced melanoma undergoing selective BRAF inhibition. J Clin Oncol (2012) 1.45
The spectrum of widespread hyperpigmentations from SLN to SUL. Arch Dermatol (2009) 1.44
Oncolytic measles virus in cutaneous T-cell lymphomas mounts antitumor immune responses in vivo and targets interferon-resistant tumor cells. Blood (2005) 1.41
Hypertext atlas of dermatopathology with expert system for epithelial tumors of the skin. J Cutan Pathol (2005) 1.40
EORTC consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome. Eur J Cancer (2006) 1.38
The multitasking organ: recent insights into skin immune function. Immunity (2011) 1.38
A Prospective Trial Comparing Q-Switched Ruby Laser and a Triple Combination Skin-Lightening Cream in the Treatment of Solar Lentigines. Dermatol Surg (2016) 1.37
A phase I, multicenter, open-label, first-in-human, dose-escalation study of the oral smoothened inhibitor Sonidegib (LDE225) in patients with advanced solid tumors. Clin Cancer Res (2014) 1.35
Aldara activates TLR7-independent immune defence. Nat Commun (2013) 1.34
Immune evasion by murine melanoma mediated through CC chemokine receptor-10. J Exp Med (2003) 1.34
Gene expression changes with age in skin, adipose tissue, blood and brain. Genome Biol (2013) 1.34
HER3 is a determinant for poor prognosis in melanoma. Clin Cancer Res (2008) 1.33
The cytokine and chemokine network in psoriasis. Clin Dermatol (2007) 1.31
Ulceration and stage are predictive of interferon efficacy in melanoma: results of the phase III adjuvant trials EORTC 18952 and EORTC 18991. Eur J Cancer (2011) 1.28
High-throughput mutation profiling of CTCL samples reveals KRAS and NRAS mutations sensitizing tumors toward inhibition of the RAS/RAF/MEK signaling cascade. Blood (2011) 1.28
Ultraviolet A and photosensitivity during vemurafenib therapy. N Engl J Med (2012) 1.28
Unraveling the autoimmune translational research process layer by layer. Nat Med (2012) 1.27
Temozolomide in combination with interferon-alfa versus temozolomide alone in patients with advanced metastatic melanoma: a randomized, phase III, multicenter study from the Dermatologic Cooperative Oncology Group. J Clin Oncol (2005) 1.27